Mark Hornfeld, DO
Ophthalmology · New York, NYNPI 1467428573
Payments from drug & device makers
Across 208 payments — averaging $217.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaleo, Inc.$41K
- AbbVie$1K
- Alcon$421
- Bausch & Lomb, A Division Of Bausch Health US, LLC$397
- Johnson & Johnson Surgical Vision, Inc.$326
- Sun Pharmaceutical Industries Inc.$311
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,8999%
- Education$490%
- Other$41,25691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaleo, Inc. | 3 | $41,256 |
| AbbVie(2 entities) | 64 | $1,030 |
| Alcon | 19 | $421 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $397 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $326 |
| Sun Pharmaceutical Industries Inc. | 16 | $311 |
| Bausch & Lomb Americas Inc. | 16 | $311 |
| Tarsus Pharmaceuticals, Inc. | 15 | $305 |
| Amgen(2 entities) | 16 | $264 |
| Eyevance Pharmaceuticals LLC | 9 | $144 |
| Harrow Eye, LLC | 5 | $113 |
| Kala Pharmaceuticals, Inc. | 4 | $96 |
| Shire North American Group Inc | 2 | $40 |
| NEW World Medical,inc. | 1 | $35 |
| Sight Sciences, Inc. | 2 | $34 |
| Glaukos Corporation | 1 | $30 |
| Dompe US, Inc. | 1 | $27 |
| Novartis | 1 | $23 |
| Thea Pharma Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$45,204 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlrexLoteprednol Etabonate | 477 | $235,329 |
| Brimonidine Tartrate | 764 | $113,046 |
| RestasisCyclosporine | 131 | $95,400 |
| LumiganBimatoprost | 160 | $82,205 |
| ProlensaBromfenac Sodium | 211 | $75,413 |
| VyzultaLatanoprostene Bunod | 142 | $63,073 |
| Loteprednol Etabonate | 221 | $57,717 |
| XdemvyLotilaner | 30 | $57,395 |
| Alphagan PBrimonidine Tartrate | 126 | $46,825 |
| ZyletTobramycin/Lotepred Etab | 69 | $35,564 |
| CombiganBrimonidine Tartrate/Timolol | 66 | $31,133 |
| XiidraLifitegrast | 45 | $30,334 |
| Bromfenac Sodium | 141 | $25,715 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 542 | $24,523 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $21,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Prolensa, Loteprednol Etabonate, Zylet | $397 | $404,024978 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,030 | $255,563483 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $311 | $109,509209 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $305 | $57,39530 claims |
| Eyevance Pharmaceuticals LLCZerviate, Tobradex St, Flarex | $144 | $31,128120 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $21 | $21,48767 claims |
| AlconSimbrinza | $421 | $13,66466 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $311 | $4,26016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.